Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-279-9845
Debt
Debt-to-Equity Ratio0.81
Current Ratio4.51
Quick Ratio4.51
Price-To-Earnings
Trailing P/E Ratio-2.98
Forward P/E Ratio-4.74
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book6.78
Profitability
EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-227.27%
Return on Assets-105.48%
Miscellaneous
Employees16
Outstanding Shares10,540,000
Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions
What is Eiger Biopharmaceuticals' stock symbol?
Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."
How were Eiger Biopharmaceuticals' earnings last quarter?
Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) released its quarterly earnings results on Friday, May, 11th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.12. View Eiger Biopharmaceuticals' Earnings History.
What price target have analysts set for EIGR?
7 equities research analysts have issued 12-month price targets for Eiger Biopharmaceuticals' shares. Their forecasts range from $24.00 to $39.00. On average, they anticipate Eiger Biopharmaceuticals' share price to reach $30.8571 in the next twelve months. View Analyst Ratings for Eiger Biopharmaceuticals.
Who are some of Eiger Biopharmaceuticals' key competitors?
Some companies that are related to Eiger Biopharmaceuticals include Fate Therapeutics (FATE), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Mesoblast (MESO), Scholar Rock (SRRK), CASI Pharmaceuticals (CASI), Vericel (VCEL), Surface Oncology (SURF), Nightstar Therapeutics (NITE), MeiraGTx (MGTX), PDL BioPharma (PDLI), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), Idera Pharmaceuticals (IDRA) and Osiris Therapeutics (OSIR).
Who are Eiger Biopharmaceuticals' key executives?
Eiger Biopharmaceuticals' management team includes the folowing people:
- Mr. David A. Cory R.Ph, MBA, Pres, CEO, Director & Bus. Founder (Age 54)
- Dr. Jeffrey S. Glenn M.D., Ph.D., Founder, Scientific Advisor & Director (Age 55)
- Dr. Joanne M. J. Quan M.D., Chief Medical Officer (Age 54)
- Mr. James P. Shaffer MBA, Chief Bus. Officer (Age 51)
- Mr. James A. Welch MBA, Chief Financial Officer (Age 60)
Has Eiger Biopharmaceuticals been receiving favorable news coverage?
Media coverage about EIGR stock has been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eiger Biopharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.91 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Eiger Biopharmaceuticals' major shareholders?
Eiger Biopharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Prosight Management LP (5.04%), Sphera Funds Management LTD. (4.51%), BlackRock Inc. (0.77%), Unterberg Capital LLC (0.76%), Eventide Asset Management LLC (0.60%) and Knott David M (0.59%). Company insiders that own Eiger Biopharmaceuticals stock include James H Welch, James P Shaffer, Jeffrey S Glenn, Joanne Quan and Ventures Fund Vi LP Vivo. View Institutional Ownership Trends for Eiger Biopharmaceuticals.
Which major investors are selling Eiger Biopharmaceuticals stock?
Which major investors are buying Eiger Biopharmaceuticals stock?
EIGR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Knott David M, Unterberg Capital LLC, Wedbush Securities Inc., Northern Trust Corp and DRW Securities LLC. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Insider Buying and Selling for Eiger Biopharmaceuticals.
How do I buy shares of Eiger Biopharmaceuticals?
Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eiger Biopharmaceuticals' stock price today?
One share of EIGR stock can currently be purchased for approximately $14.50.
How big of a company is Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals has a market capitalization of $151.78 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.
How can I contact Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals' mailing address is 350 CAMBRIDGE AVE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-279-9845 or via email at [email protected]
MarketBeat Community Rating for Eiger Biopharmaceuticals (EIGR)
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
